I-Mab Biopharma

September 10, 2020

Trillium makes the most of Pfizer’s tentative approach

September 04, 2020

Abbvie looks east for CD47

Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.

September 02, 2020

Gilead follows Roche in hitting immune system suppression

February 14, 2020

Astra throws doubt on one oncology combo approach

November 01, 2019

Upcoming events – key tests approach for Kadmon and Surface

Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.

April 15, 2019

Tracon’s latest oncology failure leaves little to excite investors

November 05, 2018

Data point - China's climbing venture capital